Last reviewed · How we verify
Aripiprazole Once-Monthly
Aripiprazole Once-Monthly is a marketed long-acting injectable antipsychotic developed by Matt Byerly, positioned in the treatment of primary psychiatric disorders. The drug's key strength lies in its once-monthly dosing, which enhances patient compliance and convenience. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Aripiprazole Once-Monthly |
|---|---|
| Also known as | Abilify Maintena® |
| Sponsor | Matt Byerly |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
- Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients (PHASE4)
- Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics (PHASE4)
- European Long-acting Antipsychotics in Schizophrenia Trial (PHASE4)
- Aripiprazole, Abilify Maintena Collaborative Clinical Protocol (NA)
- Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aripiprazole Once-Monthly CI brief — competitive landscape report
- Aripiprazole Once-Monthly updates RSS · CI watch RSS
- Matt Byerly portfolio CI